First experiment study in cytoreductive prostatectomy in patients with oligo-metastatic prostate cancer following neoadjuvant chemohormonotherapy

Cover Page

Cite item

Full Text

Abstract

Background. Nowadays there is no consensus on application of cytoreductive prostatectomy in a complex therapy in patients with oligo-metastatic prostate cancer.

Study objective: assessment of short-term results of neoadjuvant chemohormonotherapy followed by cytoreductive prostatectomy in patients with oligo-metastatic prostate cancer.

Materials and methods. Cytoreductive prostatectomy was performed in 7 patients with oligometastatic prostate cancer.

Results. Postoperative complications in 3 (42.9 %) out of 7 treated patients were classified as grade IIIb according to Clavien-Dindo scale. Post-surgical analysis of prostate tissue samples showed therapeutic pathomorphism of grade II in 3 patients (42.9 %), grade III in 1 patient (14.3 %) and grade IV in another patient (14.3 %). Urinary continence regained in all the patients. Average postoperative supervision period took 12 months. Disease progression was diagnosed in 1 patient (14.3 %).

Conclusion. Combined application of neoadjuvant chemohormonotherapy followed by cytoreductive prostatectomy can be considered as an alternative method of treatment in a properly selected group of patients with oligo-metastatic prostate cancer.

About the authors

V. O. Mager

Sverdlovsk Regional Oncological Dispensary

Author for correspondence.
Email: senior.mager@yandex.ru
ORCID iD: 0000-0002-6813-4457

Vladimir O. Mager.

29 Soboleva St., Yekaterinburg 620036.

Russian Federation

A. S. Orlov

Sverdlovsk Regional Oncological Dispensary

29 Soboleva St., Yekaterinburg 620036.

Russian Federation

T. R. Gilmutdinov

Sverdlovsk Regional Oncological Dispensary

29 Soboleva St., Yekaterinburg 620036.

Russian Federation

A. A. Veshkina

Sverdlovsk Regional Oncological Dispensary

29 Soboleva St., Yekaterinburg 620036.

Russian Federation

D. A. Kovalenko

Sverdlovsk Regional Oncological Dispensary

29 Soboleva St., Yekaterinburg 620036.

Russian Federation

A. V. Zamyatin

Sverdlovsk Regional Oncological Dispensary

ORCID iD: 0000-0002-7393-0810

29 Soboleva St., Yekaterinburg 620036.

Russian Federation

References

  1. Clinical cancer urology. Ed.: B.P. Matveev. Moskow: ABV-press, 2011. Pp. 566-734. (In Russ.).
  2. Radical prostatectomy. Ed.: D.Yu. Pushkar. Moskow: GEOTAR-Media, 2011. Pp. 35-42. (In Russ.).
  3. Grickevich A.A., Medvedev V.L., Kostin A.A., Rusakov I.G. Prognostic factors of survival rate in patients with prostate cancer. Eksperimental'naya i klinicheskaya urologiya = Experimental & Clinical Urology 2017;(4):12-19. (In Russ.). doi: 10.29188/2222-8543.
  4. Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995;13(1):8-10. doi: 10.1200/JCO.1995.13.1.8.
  5. Prostate cancer. Practical recommendations. Russian Society of Clinical Oncology. 2020. Avaliable at: https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-33.pdf. (In Russ.)
  6. Clarke N.V., Ali A., Inglebi F.C. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: longterm survival results from the STAMPEDE trial. Ann Oncol 2019;30(12):1992-2003. doi: 10.1093/annonc/mdz396.
  7. Futterer J.J., Surcel C., van der Berg R. et al. Imaging modalities in synchronous oligometastatic prostate cancer. World J Urol 2019;(37):2573-2583. doi: 10.1007/s00345-018-2416-2.
  8. Cho S.Y., Szabo Z. Molecular imaging of urogenital diseases. Semin Nucl Med 2014;44(2):93-109. doi: 10.1053/j.semnuclmed.2013.10.008.
  9. Hellman S., Weichselbaum R.R. Oligometastases revisited. Nat Rev Clin Oncol 2011;(8):378-82. doi: 10.1038/nrclinonc.2011.44.
  10. Gandaglia G., Fosati N., Stabile A. et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol 2017;72(2):289-92 doi: 10.1016/j.eururo.2016.08.040.
  11. Heidenreich A., Pfister D., Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 2015;193(3):832-8. doi: 10.1016/j.juro.2014.09.089.
  12. Culp S.H., Shellhammer P.F., Williams W.B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058-66. doi: 10.1016/j.eururo.2013.11.012.
  13. Narasimhulu D.M., Khoyru-Collado F., Chi D.S. Radical surgery in ovarian cancer. Curr Oncol Rep 2015;17(4):16. doi: 10.1007/s11912-015-0439-z.
  14. Krabbe L.M., Haddad A.Q., Westerman M.E., Margulis V. Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol 2014;32(3):615-22. doi: 10.1007/s00345-014-1286-5.
  15. Faiena I., Singer E.A., Paumill C., Kim I.Y. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). Int J Oncol 2014;45(6):2193-8. doi: 10.3892/ijo.2014.2656.
  16. Jenjitranant P., Touijer K.A. Role of surgery in oligometastatic prostate cancer. Prostate Int 2019;7(4):125-30. doi: 10.1016/j.prnil.2019.10.001.
  17. Kadmon D., Heston W.D., Fair W.R. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 1982;127(6):1238-42. doi: 10.1016/s0022-5347(17)54306-2.
  18. Heidenreich A., Fossati N., Pfister D. et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol 2018;1(1):46-53. doi: 10.1016/j.euo.2018.03.002.
  19. Sooriakumaran P., Karnes J., Stief C. et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016;69(5):788-94. doi: 10.1016/j.eururo.2015.05.023.
  20. Berkut M.V., Artem'eva A.S., Reva S.A. et al. Oncological results of neoadjuvant chemogormonal therapy in patients with high and very high-risk prostate cancer. Onkourologya = Cancer Urology 2020;16(1):54-63. (In Russ.). doi: 10.17650/1726-9776-2020-16-1-54-63.
  21. Anton A., Hasan O.K., Ballok Z. et al. Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. BJU Int 2020;126(4):433-5. doi: 10.1111/bju.15151.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.